Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML.
Bryostatin has shown promise both as a cytotoxic agent and more recently as a modulator of 1-beta-D-arabinofuranosylcytosine (ara-C) resistance. This compound is currently in phase I and II trials as a single agent. We have used the 3-4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) assay as a means of investigating the direct effects of bryostatin and the effects of co-incubating this agent with ara-C on fresh blast cells from 53 patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS). Additional studies evaluated the levels of accumulation and retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP) in cells exposed to ara-C with and without bryostatin. Cells were exposed to bryostatin at a range of concentrations (0.1-100 nM) for 48 h and at 1 nM for both modulation studies and assessment of ara-CTP production. We found bryostatin to be cytotoxic in 18/58 (31%) tests whilst potentiation of formazan production in the MTT assay was seen in 21/58 (36%) patients. On co-incubation with bryostatin, 16/58 (27%) tests showed increased cytotoxicity to ara-C. Furthermore, there was a significant increase in the accumulation of ara-CTP on co-incubation with bryostatin (p = 0.0401). We found patients with in vitro resistance were more likely to become sensitised following exposure to bryostatin (p < 0.01). This study has emphasised the need to optimise treatment regimens for individual patients using this approach.
Elgie
A W
AW
Haematology Research Department, Pembury Hospital, Kent, UK.
Sargent
J M
JM
Alton
P
P
Peters
G J
GJ
Noordhuis
P
P
Williamson
C J
CJ
Taylor
C G
CG
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000378:metabolism* / Q000494:pharmacology*; D001085:Arabinofuranosylcytosine Triphosphate / Q000032:analysis; D054713:Bryostatins; D016923:Cell Death / Q000187:drug effects; D003561:Cytarabine / Q000378:metabolism* / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000502:physiology; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D007783:Lactones / Q000494:pharmacology*; D007951:Leukemia, Myeloid / Q000473:pathology*; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects; D018942:Macrolides; D013778:Tetrazolium Salts; D013844:Thiazoles
D000970:Antineoplastic Agents; D054713:Bryostatins; D007783:Lactones; D018942:Macrolides; D013778:Tetrazolium Salts; D013844:Thiazoles; D003561:Cytarabine; D001085:Arabinofuranosylcytosine Triphosphate; C046785:bryostatin 1; C022616:thiazolyl blue